Drug intelligence / Profile preview

HSD-1930

Development stage: Unknown
Lead developer: Zhejiang Hisun Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

HSD-1930 is a selective small molecule inhibitor of 11-beta-hydroxysteroid dehydrogenase type 1 (11β-HSD1), an enzyme that catalyzes the conversion of inactive cortisone to active cortisol. Developed by Zhejiang Hisun Pharmaceutical, the drug is designed to treat metabolic disorders by reducing intracellular cortisol levels in the liver and adipose tissue, which in turn enhances insulin sensitivity and lowers blood glucose levels. It has been primarily investigated in clinical trials for the treatment of type 2 diabetes mellitus.

Targets

HSD11B1 (11-beta-hydroxysteroid dehydrogenase type 1)

Beyond the preview

Go deeper on HSD-1930.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HSD-1930.

Explore the full profile